argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
870.00
-2.27 (-0.26%)
At close: Nov 11, 2025
argenx SE Revenue
argenx SE had revenue of $1.15B in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.68B, up 92.98% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
3.68B
Revenue Growth
+92.98%
P/S Ratio
14.90
Revenue / Employee
2.30M
Employees
1,599
Market Cap
54.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 122.89M |
| Glass House Brands | 196.17M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 25.83M |
| Global Cord Blood | 196.10M |
| Zomedica | 29.45M |
argenx SE News
- 2 days ago - ARGX: Morgan Stanley Raises Price Target to $1110, Maintains Overweight Rating | ARGX Stock News - GuruFocus
- 3 days ago - ARGX Quantitative Stock Analysis - Benjamin Graham - Nasdaq
- 7 days ago - If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Benzinga
- 8 days ago - Looking Into argenx SE's Recent Short Interest - Benzinga
- 10 days ago - argenx: Sights Set On $1,000 - Seeking Alpha
- 12 days ago - This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
- 12 days ago - ARGX Downgraded by Wolfe Research to 'Peer Perform' | ARGX Stock News - GuruFocus
- 15 days ago - Guru Fundamental Report for ARGX - Benjamin Graham - Nasdaq